Aprea Therapeutics reports Q3 clinical progress, cash position.
ByAinvest
Wednesday, Nov 12, 2025 8:36 am ET1min read
APRE--
• Aprea Therapeutics reports progress in WEE1 and ATR inhibitor programs. • APR-1051 Phase 1 trial achieves stable disease in 3 out of 4 patients. • ATRN-119 RP2D of 1,100 mg once daily identified in ABOYA-119 study. • Posters featured at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. • Company has cash to fund operations through 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet